HARVARD BIOSCIENCE INC
HBIONasdaq
$6.23
↑ +4.7%Jul 17 close · end-of-day
Price
1Y↑ +53.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$27.9M
Enterprise Value
$57.0M
P/E
0.7
P/S
0.3
P/B
2.8
EV/EBITDA
34.6
PEG
—
FCF Yield
6.9%
Dividend Yield
—
Revenue (TTM)
$85.5M
Net Income (TTM)
-$9.8M
Free Cash Flow (TTM)
$1.9M
Gross Margin
58.4%
Operating Margin
-0.1%
Net Margin
-11.4%
ROE
-97.4%
ROIC
-0.2%
Debt / Equity
3.6
Net Cash
-$29.1M
Return 1Y
+37.3%
Company profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as instruments and accessories for tissue and organ-based lab research.
- CEO
- James W. Green
- Sector
- Manufacturing
- Industry
- Measuring And Control Equipment
- Employees
- 490
- Headquarters
- Massachusetts
- Website
- harvardbioscience.com
Management & directors
- Duke John DChief Executive Officer
- Frost Mark TChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
HBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.8M↓ -4.7%
Diluted EPS-$0.77↓ -93.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $102.1M | $118.9M | $113.3M | $112.3M | $94.1M | $86.5M |
| Gross profit | $58.0M | $67.7M | $60.8M | $66.1M | $54.8M | $49.9M |
| Operating income | $221,000.00 | $2.1M | -$6.9M | $1.9M | -$6.2M | -$48.6M |
| Net income | -$7.8M | -$288,000.00 | -$9.5M | -$3.4M | -$12.4M | -$56.7M |
| Diluted EPS | — | — | -$0.23 | -$0.08 | -$0.28 | -$1.28 |
| Operating cash flow | $9.3M | $1.3M | $1.2M | $14.0M | $1.4M | $6.7M |
| Free cash flow | $8.2M | $67,000.00 | -$438,000.00 | $12.2M | -$1.2M | $5.5M |
| Gross margin | 56.8% | 56.9% | 53.7% | 58.9% | 58.2% | 57.7% |
| Operating margin | 0.2% | 1.7% | -6.1% | 1.7% | -6.6% | -56.1% |
| Net margin | -7.6% | -0.2% | -8.4% | -3.0% | -13.2% | -65.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.1M | $22.0M | $24.6M | $21.8M | $20.4M | $20.6M | $23.7M | $20.8M |
| Gross profit | $13.2M | $12.8M | $14.0M | $12.2M | $11.5M | $12.0M | $14.2M | $12.2M |
| Operating income | -$2.1M | -$1.9M | $11,000.00 | -$49.7M | -$819,000.00 | $197,000.00 | $1.7M | -$1.2M |
| Net income | -$2.9M | -$4.8M | $18,000.00 | -$50.3M | -$2.3M | -$1.2M | -$2.8M | -$3.4M |
| Diluted EPS | -$0.07 | -$0.11 | $0.01 | -$11.42 | -$0.05 | -$0.03 | $10.22 | -$0.77 |
| Operating cash flow | -$846,000.00 | -$842,000.00 | $1.7M | $3.0M | $2.8M | $1.1M | -$96,000.00 | -$662,000.00 |
| Free cash flow | -$1.7M | -$1.7M | $1.4M | $2.5M | $2.7M | $877,000.00 | -$545,000.00 | -$1.1M |
| Gross margin | 57.2% | 58.1% | 57.1% | 56.0% | 56.4% | 58.4% | 59.7% | 59.0% |
| Operating margin | -9.0% | -8.5% | 0.0% | -228.1% | -4.0% | 1.0% | 7.2% | -5.7% |
| Net margin | -12.7% | -21.9% | 0.1% | -231.2% | -11.2% | -6.0% | -12.0% | -16.5% |
Company news
May 12, 2026
May 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-09 | Snider William | Award | 16,556 | $0.00 | $0.00 | filing |
| 2026-06-09 | Eade Katherine A. | Award | 16,556 | $0.00 | $0.00 | filing |
| 2026-06-09 | DENELSKY STEPHEN J | Award | 16,556 | $0.00 | $0.00 | filing |
| 2026-06-09 | Gagnon Robert E. | Award | 16,556 | $0.00 | $0.00 | filing |
| 2026-06-09 | Benson Seth Benjamin | Award | 16,556 | $0.00 | $0.00 | filing |
| 2026-03-20 | Duke John D· Chief Executive Officer | Award | 75,000 | $0.00 | $0.00 | filing |
| 2026-03-20 | Frost Mark T· Chief Financial Officer | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-03-17 | DENELSKY STEPHEN J | Buy | 10,000 | $4.87 | $48,700.00 | filing |
| 2026-03-17 | Snider William | Buy | 8,475 | $4.85 | $41,103.75 | filing |
| 2026-03-16 | Snider William | Buy | 12,525 | $4.99 | $62,499.75 | filing |
| 2026-03-16 | Duke John D· Chief Executive Officer | Buy | 5,000 | $5.01 | $25,050.00 | filing |
| 2026-03-16 | Frost Mark T· Chief Financial Officer | Buy | 5,000 | $5.00 | $25,000.00 | filing |
| 2025-12-17 | Snider William | Award | 110,000 | $0.00 | $0.00 | filing |
| 2025-09-05 | DENELSKY STEPHEN J | Award | 110,000 | $0.00 | $0.00 | filing |
| 2025-08-15 | Green James W | Tax withholding | 33,200 | $0.53 | $17,562.80 | filing |
| 2025-08-15 | Green James W | Tax withholding | 11,540 | $0.53 | $6,104.66 | filing |
| 2025-08-15 | Green James W | D | 66,036 | $0.00 | $0.00 | filing |
| 2025-08-15 | Green James W | D | 113,366 | $0.00 | $0.00 | filing |
| 2025-08-15 | Green James W | D | 49,048 | $0.00 | $0.00 | filing |
| 2025-08-15 | Green James W | D | 119,332 | $0.00 | $0.00 | filing |
| 2025-08-08 | Duke John D· Chief Executive Officer | Award | 500,000 | $0.00 | $0.00 | filing |
| 2025-08-08 | Duke John D· Chief Executive Officer | Award | 500,000 | $0.00 | $0.00 | filing |
| 2025-07-16 | Benson Seth Benjamin | Award | 110,000 | $0.00 | $0.00 | filing |
| 2025-07-16 | Eade Katherine A. | Award | 110,000 | $0.00 | $0.00 | filing |
| 2025-07-16 | Gagnon Robert E. | Award | 110,000 | $0.00 | $0.00 | filing |
Latest 25 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.